Fangzhou has signed a memorandum of understanding (MoU) with Novo Nordisk to collaborate on the management of serious chronic diseases including obesity and diabetes.
Fangzhou will harness its AI application services, treatment solutions and accessible pharmaceutical offerings, and aims to enhance health management in partnership with Novo Nordisk.
Go deeper with GlobalData
The signing ceremony was held during the third China International Supply Chain Expo in Beijing between Fangzhou founder, chairman and CEO Dr Xie Fangmin and Novo Nordisk China senior vice-president and president Christine Zhou.
Utilising Novo Nordisk’s expertise and products in diabetes and obesity care, Fangzhou intends to integrate its smart healthcare ecosystem and strong technological framework to develop a health management service.
The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education, all aimed at improving quality of life in the glucose control and weight loss sector.
The goal is to transition from a disease-centred to a health-centred model, providing patients with quality and convenient one-stop services.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDr Xie Fangmin stated: “We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.”
Both companies plan to further innovate partnerships within the medical industry’s digital landscape, aiming to improve patient outcomes and also contribute towards achieving national Healthy China 2030 objectives.
Christine Zhou stated: “With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis and early treatment are effectively implemented within smart healthcare environments.”
In June 2025, Novo Nordisk rebounded from a disappointing conclusion to its partnership with Hims & Hers by announcing a new agreement with WeightWatchers to enhance access to its weight loss medication, Wegovy (semaglutide).
